Another set of dots you can add to this matrix is the fact that Dr. Lataillade joined CYDY and GF 14 months ago (according to his Linkedin information) which coincides with when the AAV success story began making headlines. Now we know why HIV was never mentioned in the early days of Dr. J being our new CEO. The ball was already moving forward. Probably also why we were so successful and working out a repayment plan for our drug supplier. We are already 12-16 months into an HIV clinical trial plan. The 1600 patient safety summary is probably going to be the last hurdle before a major announcement is made. JMHO and I'm no expert...